213 related articles for article (PubMed ID: 16932434)
1. Do hemodialysis patients need higher doses of erythropoietin if given intravenously rather than subcutaneously?
McMahon LP
Nat Clin Pract Nephrol; 2006 May; 2(5):246-7. PubMed ID: 16932434
[No Abstract] [Full Text] [Related]
2. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.
Galliford JW; Malasana R; Farrington K
Nephrol Dial Transplant; 2005 Sep; 20(9):1956-62. PubMed ID: 15930017
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
4. [The effect of calcitriol on renal anemia in patients under chronic hemodialysis].
Abou-Khalil N; Makó J
Orv Hetil; 1996 Jul; 137(27):1469-72. PubMed ID: 9173368
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous erythropoietin in the treatment of renal anaemia.
Drinovec J; Varl J
Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
[TBL] [Abstract][Full Text] [Related]
6. European best practice guidelines 9-13: anaemia management.
Jacobs C; Hörl WH; Macdougall IC; Valderrábano F; Parrondo I; Abraham IL; Segner A
Nephrol Dial Transplant; 2000; 15 Suppl 4():33-42. PubMed ID: 11052147
[No Abstract] [Full Text] [Related]
7. [Low doses of recombinant erythropoietin in the treatment of renal anemia in patients on chronic hemodialysis and ambulatory peritoneal dialysis].
Lashutin SV; Nikolaev AIu; Ermolenko VM; Shutov EV; Bezruk VG; Ivashchenko MA
Ter Arkh; 1999; 71(6):61-3. PubMed ID: 10420460
[TBL] [Abstract][Full Text] [Related]
8. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
[TBL] [Abstract][Full Text] [Related]
9. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
10. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
Kotaki M; Uday K; Henriquez M; Blum S; Dave M
Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
[No Abstract] [Full Text] [Related]
12. Identification of poor responders to erythropoietin among children undergoing hemodialysis.
Seeherunvong W; Rubio L; Abitbol CL; Montané B; Strauss J; Diaz R; Zilleruelo G
J Pediatr; 2001 May; 138(5):710-4. PubMed ID: 11343048
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
14. Our experience with epoetins in treating renal anemia.
Bren A; Kandus A
Ther Apher Dial; 2005 Jun; 9(3):202-4. PubMed ID: 15966988
[TBL] [Abstract][Full Text] [Related]
15. The treatment of anemia in peritoneal dialysis patients.
Lacson E; Diaz-Buxo JA
Clin Nephrol; 2001 Dec; 56(6):415-27. PubMed ID: 11770793
[TBL] [Abstract][Full Text] [Related]
16. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
19. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
20. European best practice guidelines 14-16: inadequate response to epoetin.
Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Thompson K; Carveth BG
Nephrol Dial Transplant; 2000; 15 Suppl 4():43-50. PubMed ID: 11052148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
